June 29, 2026 · Form 4 insider transaction
Krishnan Mahesh sold 7,304 shares of Halozyme Therapeutics, Inc. at $75.00 per share, a transaction worth $547.8K. The trade was recorded as open-market sale under a pre-scheduled Rule 10b5-1 plan and disclosed on an SEC Form 4, filed 1 day after the transaction.
The options exercised and sales reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on March 19, 2026 in accordance with Rule 10b5-1.